Background and Aims Criminal justice-involved individuals are highly susceptible to opioid relapse and overdose-
INTRODUCTION
Drug use disorders are 25 times more prevalent among inmate populations than in the general population [1] . Upon release from incarceration, individuals with opioid use disorders face a myriad of challenges to their sobriety [2, 3] and experience high rates of relapse [4, 5] , overdose and overdose deaths [6] . These poor outcomes may be a result of the lack of support for opioid replacement therapy by US prison systems and community supervision programs (i.e. probation and parole). For example, although buprenorphine and methadone provided to inmates just prior to, or immediately following, release are associated with increased entry into community-based treatment [5, 7, 8] , treatment retention [9] [10] [11] and opioid abstinence [5, 9, 10] , recent findings indicate that fewer than 25% of prison systems offer methadone for general opioid use disorder maintenance therapy, and only 14% offer buprenorphine [12] . Moreover, fewer than half of prison systems offer referrals to methadone clinics upon release, and fewer than a third offer referrals to buprenorphine providers [12] Commonly cited reasons for not referring clients to opioid replacement therapy upon release are a preference for drug-free detoxification (methadone and buprenorphine are narcotics), and concern that the cost of therapy would be prohibitive.
Naltrexone, a full opioid antagonist, may be more acceptable to criminal justice authorities and others providing opioid use disorder therapy to this population. Because it is non-narcotic and has no abuse liability, it may be more attractive to prison systems. Additionally, the extended-release naltrexone (XR-NTX) injection blocks opioids for 30 days, thus giving the ex-inmate 'protected time' after release. We reported recently that relative to participants who received treatment as usual (TAU), subjects assigned to XR-NTX had lower rates of relapse, more time abstinent from opioids and zero overdose events, versus seven for TAU participants by the end of a 78-week follow-up period [13] .
With a current wholesale acquisition cost of $1309 per injection, the cost of XR-NTX may be a significant barrier to adoption. However, the cost of the therapy should not be viewed in isolation. The demonstrated effectiveness of the intervention would not only benefit the participant in terms of enhanced quality of life [14] , but cost offsets from the taxpayer perspective may also occur from reduced criminal activity [15] [16] [17] [18] , less recidivism [19, 20] and decreased utilization of high-cost health-care services, such as the emergency department, and fewer overdose deaths [6, 14, 15, 17] . Thus, the objective of this study was to conduct a comprehensive economic evaluation of the XR-NTX intervention [13] from the taxpayer's perspective. Our primary aims were to (1) estimate the incremental cost per quality-adjusted life-year (QALY) gained for XR-NTX participants versus those who received treatment as usual (TAU) and evaluate it relative to generally accepted value thresholds for QALYs; and (2) estimate the incremental cost per additional year of opioid abstinence for XR-NTX versus TAU participants. The findings from this study are a valuable addition to the literature, as there is a paucity of evidence regarding the economic value of XR-NTX as an opioid use disorder therapy, particularly among criminal justice-involved individuals [14] .
METHODS

Design
Our comprehensive economic evaluation followed wellestablished guidelines [21, 22] . The analyses were conducted from the perspective of the US taxpayer, as taxpayers play a pivotal role in implementing and sustaining substance use disorder interventions for individuals involved with the criminal justice system, as well as the costs associated with their subsequent therapy and other health care. As can be seen in Table 1 , 98% of the study population was on some form of public insurance. The taxpayer is also responsible primarily for the costs to the criminal justice system associated with recidivism. Incremental costs for XR-NTX participants relative to TAU participants were estimated by valuing the resources associated with the intervention, as well as potential offsets associated with more appropriate healthcare service utilization and reduced criminal activity. These incremental costs were then evaluated relative to incremental gains in both economic (QALYs) and clinical (time abstinent) effectiveness measures. Finally, we assessed uncertainty and conducted sensitivity analyses.
The XR-NTX randomized effectiveness trial
The trial evaluated in this study was a multi-site open-label randomized-controlled effectiveness study comparing XR-NTX to TAU for the prevention of opioid relapse among community-dwelling participants involved with the criminal justice system [13] . The five independently funded study sites were: University of Pennsylvania (Philadelphia), New York University School of Medicine and Bellevue Hospital Center (New York), Rhode Island Hospital and Brown University (Providence, Rhode Island), Columbia University Medical Center (New York) and Friends Research Institute (Baltimore). At the time of randomization, eligible participants: were residing in the community; were between the ages of 18 and 60 years; had a prior DSM-IV diagnosis of opioid dependence; were serving an adjudicated sentence under supervision (e.g. parole, probation, etc.), or in the past year had been released from incarceration, a plea-bargain arrangement or community supervision; were opioid free (confirmed with a urine analysis); were not receiving treatment for another drug or alcohol use disorder that would interfere with the XR-NTX therapy; were not pregnant; did not have a potentially complicating psychiatric disorder or medical condition; were not receiving long-term opioid therapy for chronic pain; and had not been hospitalized in the past 3 years for a drug overdose. Participation was voluntary, and participants were not referred directly from criminal justice authorities. Full details of the study rationale and design are available elsewhere [23] .
A total of 308 individuals were randomized successfully to either six monthly injections of XR-NTX (n = 153) or TAU (n = 155). The XR-NTX group received medical management counseling at each visit, which included counseling for medication side effects, recovery and treatment participation, and relapse and overdose prevention, as well as referrals to community treatment resources. The TAU group also received monthly assessments with similar counseling for relapse and overdose prevention, and referrals to community treatment resources. Participants were screened for opioids, and asked about their opioid use twice a week during the 25-week intervention, as well as at the 52-and 78-week follow-up visits.
Relative to TAU participants, those assigned to XR-NTX were significantly less likely to relapse [odds ratio (OR) = 0.43; 95% confidence interval (CI) = 0.28-0.65], had a longer median time to relapse (hazard ratio = 0.49; 95% CI = 0.36-0.68) and had more urine analyses that tested negative for opioids (OR = 2.3; 95% CI = 1.48-3.54). These effects waned after treatment discontinuation; however, during the 78-week study period there were seven overdose events among TAU participants, while XR-NTX patients did not experience any (P = 0.02).
Cost measurement
Study-provided XR-NTX therapy
The cost of the study-provided therapy was based on the resources utilized to deliver the 380 mg injection of XR-NTX within a medical management visit. Approximately 69% of our study population was on some form of public insurance at the beginning of the study, and another 29% were uninsured; therefore, the cost of the XR-NTX injection was valued according to an estimated publicsector price. According to a report from the Congressional Budget Office [24] , the Medicaid net manufacturer price, which also extends to clinics funded by the Public Health Service and disproportionate share hospitals, is 51% of the wholesale acquisition cost, on average. The current wholesale acquisition cost of XR-NTX is $1309 per injection, making the public-sector price approximately $668 per injection. Medical management visits were conducted typically by a certified registered nurse practitioner (CRNP) during an average time span of 30 minutes. The CRNP's time was valued according to the mean annual salary of $97 990 reported by the Bureau of Labor Statistics (BLS) [25] , and the BLS' estimated benefit rate of 30.2% for the health care and social assistance industry group; business-overhead expenses attributable to a unit of labor were not included.
Non-study services
Medical and non-medical resource use outside of the study was self-reported via the Non-Study Medical Services form, which was administered by research staff. This information was collected at baseline, monthly during the 25-week intervention and at the 52-and 78-week follow-up points. Non-study opioid use disorder therapy resources that were tracked included out-patient treatment, residential stays, hospital detoxification admissions and medications (oral and depot naltrexone, buprenorphine and methadone).
Other non-study medical resources that were measured included out-patient medical-care visits, non-detox inpatient admissions, emergency department visits and mental health sessions with a counselor or psychiatrist. Unit cost estimates were obtained from various sources. All costs are in US dollars and were converted to 2014 values using the Consumer Price Index. All values measured beyond a year from baseline were discounted for time-preference using the recommended rate of 3% [21, 26] . Oral naltrexone, buprenorphine and methadone were valued according to their adjusted wholesale acquisition cost [27] . The costs for a residential rehabilitation stay, a hospital detox and non-detox admission and an emergency department visit were obtained from the 2003 MEDSTAT MarketScan database for beneficiaries with substance use disorders who were between the ages of 12 and 25 years [28] . These services were valued at $520, 683, 1267 and 512 (2014 US$), respectively. The cost of a visit to a physician ($128/hour), nurse practitioner ($67/hour), psychiatrist ($126/hour) or counselor ($33/hour), was valued using the respective mean salary and benefit level from the BLS [25] , as described above. The estimated mean cost of an out-patient treatment visit for a substance use disorder ($14) was obtained from the Alcohol and Drug Services Study on the costs of substance use treatment in the specialty sector [29] .
Criminal justice activities
Interactions with the criminal justice system were measured via arrests (obtained from individual state-level criminal records) and self-reported parole-officer visits (obtained via the Criminal and Legal Activities form, which was administered at the same time as the Non-Study Medical Services form).
The resources associated with arrests for particular crimes were valued according to estimates developed by McCollister et al. [30] that reflect the direct costs to the criminal justice system. Specifically, the estimates reflect the costs associated with police protection, legal and adjudication and corrections resources. Visits to probation officers were valued using mean salary and benefit estimates obtained from the BLS ($40/hour) [25] .
Effectiveness measurement
We calculated two measures of effectiveness: clinical and economic. The clinical effectiveness outcome is a measure of time free from opioids, and is operationalized as the predicted proportion of the year that a participant was abstinent from opioids; we refer to this outcome as an abstinent year. Time abstinent is an important measure of effectiveness for clinical stakeholders, and calculating cost per abstinent year enables comparisons with existing economic evaluations that have utilized similar effectiveness measures [14] . Abstinence was based on urine samples and self-reported opioid-use assessments collected at baseline, every 2 weeks during the 25-week intervention period and at weeks 52 and 78. A missing urine sample was calculated as 5 days of opioid use [13] .
While clinical outcome measures may be useful to some stakeholders, they are problematic in that they fail to capture other consequences associated with opioid misuse, such as changes in quality of life. Therefore, as our economic effectiveness outcome, we calculated QALYs which reflect both the time spent in a given health state and the quality of life associated with that particular state, and are recommended by the Panel on Cost Effectiveness in Health and Medicine as the primary outcome measure in economic evaluation studies [26] . The health-related quality-of-life preference weights used to calculate QALYs were obtained from the EuroQol five dimensions questionnaire (EQ-5D) [31, 32] , which was administered at baseline, every 4 weeks during the intervention and at the 52-and 78-week follow-up visits. The EQ-5D is the most widely used generic, preference-based health-related quality-of-life instrument [33] . It produces a score between À0.594 and 1, where a score of 0 reflects death, a score less than 0 reflects a health state perceived to be worse than death and a score of 1 reflects 'perfect health'. As with the cost figures, all values measured between 52 and 78 weeks were discounted for time-preference using the recommended rate of 3% [21, 26] .
Cost-effectiveness measurement
Cost-effectiveness was measured via incremental costeffectiveness ratios (ICERs). The ICER is a measure of the cost differential between the XR-NTX and TAU groups, divided by the effectiveness differential between the two groups. Two different ICERs (one for each measure of effectiveness) were calculated at weeks 25 and 78.
Analysis
Baseline patient characteristics were tested using χ 2 tests
for categorical variables and t-tests for continuous variables to indicate the success of randomization and test whether the study arms differed significantly with regard to factors that were not accounted for in the randomization process, such as insurance status, relevant resources utilized prior to baseline and health-related quality of life. Due to the different data-generating mechanisms, individual multivariable regressions were estimated via generalized linear models (GLMs) to predict the mean monthly costs associated with study-provided therapy, non-study opioid use disorder therapy, other non-study medical resources and criminal justice activities [21] . The same process was applied to the mean number of days abstinent per month, and average monthly health-related quality-of-life preference weights. The family functions for the GLMs were chosen with the assistance of the modified Parks test, while the link functions were based on the Pregibon link, Pearson correlation and modified Hosmer & Lemeshow tests [21] . All predicted mean values were estimated using the method of recycled predictions [21] . Missing data were not an issue for study-provided therapy (because this information was recorded as it was provided to the participant) or for arrests (because this information was gathered from criminal records). In total, 3% of non-study opioid use disorder therapy and other non-study medical resource data were missing, as were 9% of self-reported parole visit data, 20% of opioid abstinence data and 21% of health-related quality of life data. Missing data were addressed by way of inverse probability weighting in the GLM framework. Inverse probability weighting has been shown to be effective at addressing missing-data bias when data are missing at random [34] , which appears to be the case here [13] .
Total per-participant direct costs were calculated by summing the relevant monthly predicted mean values during the time-frame of interest. That is, the costs associated with the intervention time-frame were assessed by summing the monthly values over the first 25 weeks, while the costs associated with the entire study period, including follow-up, were assessed by summing the values over all 78 weeks.
QALYs were estimated using the area-under-the-curve methodology and the predicted health-related quality of life preference weights. Abstinent years were calculated by summing the monthly predicted number of abstinent days during the relevant time-periods of 25 and 78 weeks.
To account for sampling uncertainty, we estimated standard errors and P-values using non-parametric bootstrapping techniques [21] . The uncertainty surrounding each ICER was evaluated through the use of an acceptability curve, which displays the probability that the intervention's cost per QALY or cost per abstinent year falls below a given willingness-to-pay threshold, and thus would be considered cost-effective at that value [21, 22, 35] . We tested the sensitivity of our results by estimating all models using ordinary least squares (OLS), as opposed to GLM, and by estimating a lower-bound price. For the latter, we used a deeply discounted price of $496, which is the lowest we found via discussions with clinicians providing this service to publicly insured patients, and subtracted the cost of the first injection, as Alkermes (the producer of XR-NTX/Vivitrol ® ) commonly donates the first injection to patients who are part of a comprehensive reentry program [36] .
RESULTS
The baseline descriptive statistics for XR-NTX and TAU participants are displayed in Table 1 . The groups did not differ significantly by any of the measured characteristics, including the five health-related quality-of-life dimensions, and the value of health-care and criminal justice system resources used in the 90 days prior to baseline. Participants in both groups were, on average, in their mid-40s, and the majority of participants in each group were male, black/African American and insured by some form of public insurance. Table 2 contains the predicted mean costs for each of the aforementioned resource categories, by time-period. The incremental average direct cost of the 25-week XR-NTX intervention was $3243 [standard error (SE) = 703, P < 0.001]. By 78 weeks the incremental average direct cost had fallen to $2292 (SE = 1081, P = 0.03). The costs associated with non-study opioid use disorder therapy were lower for XR-NTX relative to TAU at both 25 and 78 weeks, but not significantly so (25 weeks: -$261, SE = 336, P = 0.44; 78 weeks: -$331, SE = 346, P = 0.34). The cost of other medical resources used outside the study was also lower for XR-NTX versus TAU at 25 and 78 weeks but, again, neither of these differences reached statistical significance at the 5% level (25 weeks: -$175, SE = 133, P = 0.19; 78 weeks: -$257, SE = 224, P = 0.25). The predicted mean direct costs to the criminal justice system were $432 (SE = 277) higher for XR-NTX than TAU at 25 weeks, but the difference was not statistically significant (P = 0.12). At 78 weeks this figure was $367 (SE = 882) lower for XR-NTX but, again, the difference did not achieve statistical significance (P = 0.68). As shown in Table 3 , criminal activity was minimal among both groups. Costs were not sensitive to the estimation technique (see Fig. 1 ). That is, overall, the costs estimated via the more robust and efficient GLM regression are very similar to those estimated using the more transparent OLS Figure 1 Sensitivity analysis of costs. XR-NTX -extended release naltrexone; TAU = treatment as usual; OLS = ordinary least squares regression regression, as well as to the raw mean values. However, the costs are sensitive to the price of the XR-NTX injection.
Costs
Effectiveness
The predicted mean outcome values for each group, by time-period, are displayed at the bottom of Table 2 . The annualized QALYs gained by XR-NTX participants exceeded those gained by TAU participants by 0.04 (SE = 0.02, P = 0.02) at 25 weeks. Although not statistically significant, the QALYs gained for XR-NTX versus TAU are also larger at 78 weeks (0.02, SE = 0.02, P = 0.25). Annualized abstinent years were also higher for XR-NTX relative to TAU at both 25 weeks (0.14, SE = 0.03, P < 0.001) and 78 weeks (0.09, SE = 0.03, P = 0.004).
Cost-effectiveness
Given that the power to detect a joint difference in costs and effects can exceed the power to detect a difference in either one independently, it is important to evaluate the two jointly via the ICER, regardless of whether a significant difference exists in either one independently [21] . The ICERs for each outcome can be found in Table 4 , while the acceptability curves displaying the uncertainty around these figures can be found in Figs 2 and 3 for cost-per-QALY and cost-perabstinent year, respectively. The cost-per-QALY ICER point estimate at 25weeks is$162 150. By78 weeks the ICER falls to $76 400, due largely to a smaller incremental average direct cost resulting from larger, albeit statistically insignificant, cost offsets in non-study opioid use disorder therapy, other non-study health-care services and criminal justice resources. At 25 weeks, we can be 10% certain that the XR-NTX intervention would be considered good value by the taxpayer iftheyare willing to pay $100 000 per QALY, 62% certain at a $200 000 per QALY threshold, 84% certain at $300 000 per QALY and 90% certain at $400 000 per QALY. At 78 weeks, the cost-effectiveness probabilities are 59% at a value threshold of $100 000, 76% at $200 000, 81% at $300 000 and 82% at $400 000.
Relative to the cost-per-QALY ICERs, the cost-perabstinent-year ICERs are lower, with much less uncertainty. At 25 weeks the estimated cost per abstinent year is $46 329, and by 78 weeks it drops to $16 371.
From the taxpayer's perspective, we can be 95% confident that the intervention would be considered a wise investment at $90 000 per abstinent year at 25 weeks and $500 per abstinent year at 78 weeks.
DISCUSSION
With an incremental average direct cost of $3243, the 25-week XR-NTX intervention was significantly more expensive than TAU, even after accounting for potential cost-offsets associated with other forms of opioid use disorder therapy and non-study health-care services, both of which were lower for XR-NTX versus TAU participants, but did not reach statistical significance at the 5% level. We found no significant between-group differences in the cost associated with criminal justice resource utilization, which was higher at 25 weeks for XR-NTX relative to TAU participants, but lower at 78 weeks. However, XR-NTX participants experienced significant increases in QALYs at 25 weeks, and days abstinent at both 25 and 78 weeks, relative to TAU.
One of the most, if not the most, commonly cited cost per QALY threshold values in the United States is $50 000 [37] , which has been in use since approximately 1982 [38] . Simply adjusting for inflation brings this figure to approximately $155 680 (2014 US$). Using the estimated public-sector price of XR-NTX, our 25-week cost per QALY point estimate is slightly higher than this threshold for defining value, while the 78-week point estimate is well below it. Furthermore, recent evidence indicates that in the United States a range of approximately $100 000 to $400 000 (2014 US$), after adjusting for inflation, per QALY would be consistent with observed spending decisions [39, 40] . Given the impossible task of defining a single cost per QALY value threshold in the United States, where health-care budgets are less rigid and there are many types of health-care decision-makers, Neumann et al. [40] recommend focusing on a range of $100 000 to $200 000 per QALY. Using this range of value thresholds, the intervention has between a 10 and 62% chance of being considered cost-effective at 25 weeks, and between a 59 and 76% chance at 78 weeks. However, at the wholesale acquisition cost, the respective percentages drop to 0 and 12% at 25 weeks, and 23 and 57% at 78 weeks. To the best of our knowledge, this is the first study to evaluate the cost-effectiveness of XR-NTX as an opioid use disorder therapy using QALYs as an effectiveness measure [14] .
The cost-per-abstinent-year point estimates are low by comparison, and are associated with a relatively low level of uncertainty. The problem is that, unlike QALYs, generally accepted value thresholds do not exist for abstinent outcomes. None the less, these estimates will probably be of great interest to stakeholders who value Table 4 Incremental cost-effectiveness ratios. 
STRENGTHS AND LIMITATIONS
This study is one of the few to evaluate the costeffectiveness of XR-NTX as an opioid use disorder treatment, and is the first to do so in a clinical trial among a criminal justice population and using QALYs as a measure of effectiveness.
Although missing data are a concern, the total rate of missing data was low throughout the intervention period, reaching a high of 14 and 10% among XR-NTX and TAU participants, respectively, in week 25 of the intervention period, and climbing to 25 and 19%, respectively, by week 52 of follow-up. Moreover, as the data seem to be missing at random, we were able to address the missingness using inverse probability weighting, a method shown to be effective at removing missing-data bias [34] . Our criminal justice cost estimates are not comprehensive for two reasons. First, criminal records were only gathered from the state in which the participants' research site was located and do not include federal crimes. However, we have no reason to believe that this would affect one arm disproportionately, relative to the other. Secondly, our cost estimates were limited to the 13 offenses valued by McCollister et al. [30] , although these 13 offenses are among the costliest to society and account for 72% of all arrests made during the study period. Furthermore, the XR-NTX and TAU groups did not differ significantly with regard to the unvalued crime categories. The 78-week time horizon is a limitation for a therapy that is likely to have longer-term consequences. However, we show improved economic outcomes from 25 to 78 weeks, suggesting that XT-NRT may have favorable longer-term consequences, but more evidence is needed to extrapolate confidently and thus out of scope for this paper [21, 22] . Furthermore, our economic conclusions for XR-NTX are relative to TAU and not the evidence-based standard of care, methadone or buprenorphine maintenance therapy. While we are unaware of an economic study comparing methadone or buprenorphine maintenance therapy to TAU among criminal justice-involved individuals, it is possible that it is a cost-effective alternative to TAU. Finally, our study population is probably not representative of all criminal justice populations (please see the inclusion and exclusion criteria in the discussion of the trial above).
CONCLUSIONS
Our study provides much-needed information regarding the economic value of extended-release naltrexone (XR-NTX) as an opioid use disorder therapy, specifically as it pertains to community-dwelling indiviuals involved with the criminal justice system. XR-NTX is an effective therapy in terms of increased QALYs and time abstinent. With regard to the outcome of QALYs, our findings indicate that the cost-effectiveness of XR-NTX is sensitive to the price of the injection. For example, even at the heavily discounted price of $668 per injection, this therapy is on the threshold of being cost-effective for the taxpayer at generally accepted value thresholds for QALYs [39] ; however, the argument that XR-NTX is 'good value' strengthens as the price decreases. Stakeholders interested primarily in the clinical outcome of abstinence may find the intervention to be a good investment at these discounted prices, depending on the amount they are willing to pay. We did not find significant cost-offsets associated with the intervention; thus, its value lies in its ability to improve abstinence and quality of life, and the fact that it is more likely to be acceptable to criminal justice authorities. Future studies examining the effectiveness of XR-NTX among a higher-risk criminal justice population, such as pre-release prisoners, may have more power to detect such offsets.
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